惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

量子位
Recent Announcements
Recent Announcements
D
Docker
V
V2EX
阮一峰的网络日志
阮一峰的网络日志
Vercel News
Vercel News
Microsoft Security Blog
Microsoft Security Blog
The GitHub Blog
The GitHub Blog
U
Unit 42
奇客Solidot–传递最新科技情报
奇客Solidot–传递最新科技情报
月光博客
月光博客
腾讯CDC
B
Blog
博客园_首页
罗磊的独立博客
D
DataBreaches.Net
IT之家
IT之家
酷 壳 – CoolShell
酷 壳 – CoolShell
L
LangChain Blog
aimingoo的专栏
aimingoo的专栏
MongoDB | Blog
MongoDB | Blog
GbyAI
GbyAI
Stack Overflow Blog
Stack Overflow Blog
M
MIT News - Artificial intelligence

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Cencora, Inc. (COR) Presents at BofA Securities 2026 Chin...
2026-05-14 · via All Articles on Seeking Alpha

Q2: 2026-05-06 Earnings Summary

EPS of $4.75 beats by $0.02

 | 

Revenue of

$78.36B

(3.85% Y/Y)

misses by $2.68B

Cencora, Inc. (COR) BofA Securities 2026 China Conference May 13, 2026 11:00 AM EDT

Company Participants

Robert Mauch - President, CEO & Director
James Cleary - Executive VP & CFO
Bennett Murphy - Senior VP Of Investor Relations & Enterprise Productivity and Treasury

Conference Call Participants

Allen Lutz - BofA Securities, Research Division

Presentation

Allen Lutz
BofA Securities, Research Division

All right. Good morning. Welcome to day 2 of the BofA Global Healthcare Conference. My name is Allen Lutz. I run health care, tech and distribution here at Bank of America. We are excited to have the Cencora team here. We have President and CEO, Bob Mauch; EVP and CFO, Jim Cleary; and Head of Investor Relations and Enterprise Productivity, Bennett Murphy. Thank you to the team for joining us. Really appreciate it.

I'll start with Bob. You reported earnings last week. I guess before we dive in, is there anything you want to highlight about the quarter or just any thoughts there?

Robert Mauch
President, CEO & Director

Yes. First, thanks, Allen. Thanks for having us. We're excited to be here to talk about Cencora. And I'll say we don't take the recent pullback in our shares lightly, and we wanted to be here to explicitly express our confidence in our full year guidance as well as our long-term guidance. We recognize that there's some noise around the quarter, and so we want to do everything that we can to make sure everybody understands why we have that confidence. And I'll also note that in our press release, we announced that we were resuming share repurchases and that we expect to repurchase $1 billion in shares by the end of the calendar year.

Maybe most importantly, longer term is why we're confident and we have a very focused pharmaceutical-centric strategy that